NuGen Medical Devices Inc.
NGMD.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 351.80% | -35.12% | 95.56% | 665.43% | 2,683.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 351.80% | -35.12% | 95.56% | 665.43% | 2,683.87% |
| Cost of Revenue | 525.24% | -42.47% | 194.34% | 528.80% | 3,422.22% |
| Gross Profit | 250.46% | -28.72% | 53.54% | 1,124.32% | 2,386.36% |
| SG&A Expenses | 10.56% | -73.22% | -11.19% | 88.92% | 114.37% |
| Depreciation & Amortization | -14.35% | -12.18% | -4.48% | -35.92% | 39.08% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.44% | -67.88% | -9.61% | 72.69% | 109.01% |
| Operating Income | -0.04% | 68.24% | 11.13% | -63.00% | -98.82% |
| Income Before Tax | -27.04% | 60.89% | 13.20% | -45.74% | -86.31% |
| Income Tax Expenses | 1,480.00% | -- | -- | 1,977.78% | -- |
| Earnings from Continuing Operations | -27.46% | 61.01% | 13.20% | -47.10% | -86.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.46% | 61.01% | 13.20% | -47.10% | -86.37% |
| EBIT | -0.04% | 68.24% | 11.13% | -63.00% | -98.82% |
| EBITDA | -1.38% | 72.75% | 12.35% | -65.18% | -118.91% |
| EPS Basic | -8.70% | 70.64% | 48.44% | 36.24% | 10.68% |
| Normalized Basic EPS | -3.33% | 53.73% | 48.75% | 41.00% | 11.76% |
| EPS Diluted | -8.70% | 70.64% | 48.44% | 36.24% | 10.68% |
| Normalized Diluted EPS | -3.33% | 53.73% | 48.75% | 41.00% | 11.76% |
| Average Basic Shares Outstanding | 17.73% | 31.52% | 67.85% | 131.06% | 108.03% |
| Average Diluted Shares Outstanding | 17.73% | 31.52% | 67.85% | 131.06% | 108.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |